Compare AstraZeneca plc (AZN) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Vanguard Total World Stock Index Fund ETF — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while Vanguard Total World Stock Index Fund ETF trades at $161.56. The key difference: AstraZeneca plc pays a 2.01% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | VT | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $161.30 |
52-Week Low | $147.06 | $132.19 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Vanguard Total World Stock ETF (VT) trades at $161.53, up 0.35% on the day, with a bullish technical signal from moving averages. The ETF offers diversified global equity exposure across more than 10,000 stocks, with a low expense ratio of 0.06% (Vanguard, 2026). Recent news highlights institutional activity, including Barry Investment Advisors reducing its stake by 18.7% in Q2 2026 (Defense World, 2026-08-10).
VT provides broad market access but faces risks from trade policy uncertainty and potential market volatility. The neutral oscillator signal and overbought RSI levels suggest near-term consolidation. Long-term appeal lies in cost-efficient global diversification, though investors should weigh geopolitical risks against the fund's historical resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
